Matches in SemOpenAlex for { <https://semopenalex.org/work/W2301514247> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- W2301514247 endingPage "282" @default.
- W2301514247 startingPage "274" @default.
- W2301514247 abstract "Purpose: To investigate the tomographic efficacy of intravitreal bevacizumab (IVB) combined with posterior subtenon triamcinolone (PST) in patients with diabetic macular edema.Methods: This is a retrospective, comparative, and nonrandomized study. From January 2008 to December 2009, patients with diabetic macular edema but without prior macular laser or any intervention were enrolled. The eyes were divided into one of two study arms: the IVB group, patients who received 1.25 mg of intravitreal bevacizumab (55 eyes); and the IVB/PST group, patients who received 1.25 mg of intravitreal bevacizumab and 20 mg of posterior subtenon triamcinolone (46 eyes). Primary outcome measures included change in central foveal thickness (CFT) in 1 mm and central macular volume (CMV) in 5 mm of diameter by spectral-domain optic coherence tomography 1, 2, 3 and 6 months after one injection. Complications after injections were recorded. The intra-group difference was compared with Wilcoxon sign-rank test, and the inter-group difference was compared with Wilcoxon rank-sum test.Results: Both CMV and CFT were significantly reduced 1, 2 and 3 months after injections in both groups (p ＜ 0.05), but not significantly decreased 6 months after injections (p ＞ 0.05). There was no significant difference in CMV and CFT at baseline or at 1, 2, 3 and 6 months following injections between the two groups. There were 3 eyes (3/55, 5.5%) with proliferative diabetic retinopathy and active fibrovascular proliferation having subsequent tractional retinal detachment in the IVB group. There were no eyes with elevated intraocular pressure, retinal detachment, and infectious endophthalmitis in the two groups.Conclusions: Both regimens (IVB and IVB/PST) by single injection were useful in treating diabetic macular edema within 3 months. Posterior subtenon triamcinolone did not prolong or enhance the effect of intravitreal bevacizumab for managing diabetic macular edema. Potential complications should be addressed after intravitreal bevacizumab." @default.
- W2301514247 created "2016-06-24" @default.
- W2301514247 creator A5053084323 @default.
- W2301514247 date "2011-06-01" @default.
- W2301514247 modified "2023-09-23" @default.
- W2301514247 title "Tomographic Changes in Diabetic Macular Edema Managed by Intravitreal Bevacizumab with or without Posterior Subtenon Injection of Triamcinolone" @default.
- W2301514247 doi "https://doi.org/10.30048/actasos.201106.0008" @default.
- W2301514247 hasPublicationYear "2011" @default.
- W2301514247 type Work @default.
- W2301514247 sameAs 2301514247 @default.
- W2301514247 citedByCount "0" @default.
- W2301514247 crossrefType "journal-article" @default.
- W2301514247 hasAuthorship W2301514247A5053084323 @default.
- W2301514247 hasConcept C118487528 @default.
- W2301514247 hasConcept C134018914 @default.
- W2301514247 hasConcept C141071460 @default.
- W2301514247 hasConcept C2776694085 @default.
- W2301514247 hasConcept C2777802072 @default.
- W2301514247 hasConcept C2778903070 @default.
- W2301514247 hasConcept C2779829184 @default.
- W2301514247 hasConcept C2780347916 @default.
- W2301514247 hasConcept C2780827179 @default.
- W2301514247 hasConcept C2781100027 @default.
- W2301514247 hasConcept C555293320 @default.
- W2301514247 hasConcept C71924100 @default.
- W2301514247 hasConceptScore W2301514247C118487528 @default.
- W2301514247 hasConceptScore W2301514247C134018914 @default.
- W2301514247 hasConceptScore W2301514247C141071460 @default.
- W2301514247 hasConceptScore W2301514247C2776694085 @default.
- W2301514247 hasConceptScore W2301514247C2777802072 @default.
- W2301514247 hasConceptScore W2301514247C2778903070 @default.
- W2301514247 hasConceptScore W2301514247C2779829184 @default.
- W2301514247 hasConceptScore W2301514247C2780347916 @default.
- W2301514247 hasConceptScore W2301514247C2780827179 @default.
- W2301514247 hasConceptScore W2301514247C2781100027 @default.
- W2301514247 hasConceptScore W2301514247C555293320 @default.
- W2301514247 hasConceptScore W2301514247C71924100 @default.
- W2301514247 hasIssue "2" @default.
- W2301514247 hasLocation W23015142471 @default.
- W2301514247 hasOpenAccess W2301514247 @default.
- W2301514247 hasPrimaryLocation W23015142471 @default.
- W2301514247 hasRelatedWork W1594857821 @default.
- W2301514247 hasRelatedWork W1982460180 @default.
- W2301514247 hasRelatedWork W1999343243 @default.
- W2301514247 hasRelatedWork W2020224800 @default.
- W2301514247 hasRelatedWork W2048310877 @default.
- W2301514247 hasRelatedWork W2063385448 @default.
- W2301514247 hasRelatedWork W2067332212 @default.
- W2301514247 hasRelatedWork W2070126836 @default.
- W2301514247 hasRelatedWork W2093839147 @default.
- W2301514247 hasRelatedWork W2150171454 @default.
- W2301514247 hasRelatedWork W2186450107 @default.
- W2301514247 hasRelatedWork W2275773128 @default.
- W2301514247 hasRelatedWork W2334744807 @default.
- W2301514247 hasRelatedWork W2431511487 @default.
- W2301514247 hasRelatedWork W2597839750 @default.
- W2301514247 hasRelatedWork W2911773818 @default.
- W2301514247 hasRelatedWork W2938888505 @default.
- W2301514247 hasRelatedWork W3030400076 @default.
- W2301514247 hasRelatedWork W3031471749 @default.
- W2301514247 hasRelatedWork W3186539005 @default.
- W2301514247 hasVolume "50" @default.
- W2301514247 isParatext "false" @default.
- W2301514247 isRetracted "false" @default.
- W2301514247 magId "2301514247" @default.
- W2301514247 workType "article" @default.